Xolair®

Understanding Xolair®

Xolair® is used to treat allergic and inflammatory conditions, including moderate-to-severe persistent asthma, chronic spontaneous urticaria (CSU), and nasal polyps. It works by targeting and binding to immunoglobulin E (IgE), a key antibody involved in allergic reactions. By preventing IgE from activating mast cells, Xolair® reduces inflammation, minimizes asthma attacks and hives, and helps control the growth of nasal polyps.

How Xolair® Works:

• Binds to IgE, preventing it from triggering allergic reactions.
• Reduces inflammation, improving asthma control and reducing hives.
• Helps shrink nasal polyps, improving breathing and reducing symptoms.

FDA Approvals:

• Moderate-to-severe Persistent Allergic Asthma (ages 6+): Approved on June 20, 2003
• Chronic Spontaneous Urticaria (CSU) (ages 12+): Approved on March 21, 2014
• Nasal Polyps (CRSwNP) (ages 18+): Approved on December 1, 2020

For more information, please visit the Xolair® patient website and speak with your healthcare provider to determine if Xolair® is the right treatment option for you.